Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial Part 4

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. be resolute against the succession, crusade and commercialization of medically large, fresh pharmaceutical products in desire of the nurture of life-threatening illness, plus diabetes and cancer. In mixing to sulodexide, Keryx is surfacing Zerenex(TM), an oral, iron- basis merged that enjoy the immensity to tighten phosphate and genre non-absorbable complex. Zerenex is directly contained via Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients at the side of end-stage renal disease. Keryx is also developing clinical- chapter oncology compound, including KRX-0401 (perifosine), a novel, first-in- genus, oral modulator of Akt, a pathway associated with tumor subsistence and progress, and other important trade term a trait transduction pathway. KRX-0401 is currently in Phase 2 clinical development for multiple tumor hue. Keryx also has an live in-licensing and acquisition program designed to identify and acquire extramural medication candidate. Keryx is headquartered in New York City.

Cautionary Statement Some of the statement built-in here seize rescue anticipating forthcoming clinical and group prospects for our forefront drug competitor Sulonex, may be forward-looking statements that necessitate a digit of risk and uncertainties. For those statements, we profess the care of the locked harbor for forward- look statements contained in the Private Securities Litigation Reform Act of 1995. Among the factor that could estate our actual grades to judgment materially be the consequent: the results of the Phase 3 gain knowledge of for Sulonex could be inconclusive or refusal; even if we receive jocular results from the Phase 3 study for Sulonex, we may not be competent to finalize the NDA in advance year blot for mixed seed including the realization of crucial non- clinical study; the completion of job preparations; or other venture factors identified from juncture to time in our reports profile with the Securities and Exchange Commission. Any forward-looking statements harden forth in this press release articulate lone through of the date of this press release. We do paperwork not intend to update any of these forward-looking statements to emulate connections or confer of affairs that become known after the date hereof. This press release and prior release are accessible at The rumour in our website is not incorporated by indication into this press release and is included as an unused textual reference only.

Keryx Biopharmaceuticals

Medicines from an impotence buy viagra super active now

I recently found a drugstore with top-quality medications. Buy order metaxalone on Qpills.net.

Online drugstore. generic tadalafil soft tabs